Cancer vaccine MUC-1 - Immutep Limited

Drug Profile

Cancer vaccine MUC-1 - Immutep Limited

Alternative Names: CVac; M-FP cancer vaccine; Mannan-MUC1 fusion protein; MUC1 dendritic cell vaccine

Latest Information Update: 04 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Prima Biomed
  • Developer Prima BioMed
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 28 Nov 2017 Prima BioMed is now called Immutep Limited
  • 19 May 2015 Updated efficacy results from a phase II trial in Ovarian cancer released by Prima BioMed
  • 01 Apr 2015 Prima BioMed completes a phase II trial for Ovarian cancer in USA and Australia (NCT01068509)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top